Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Six weeks versus six months of oral valganciclovir in infants with symptomatic congenital cytomegalovirus infection
2008-005508-14Phase 3Completed
- Sponsor
- University College London
- Start
- Mar 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of valganciclovir in congenital cytomegalovirus infection (cCMV) (2 arms), sponsored by University College London. Primary endpoint: Change in best ear hearing assessment. Started Mar 2010; status: completed.
02
Drugs
valganciclovir
03
Conditions
congenital cytomegalovirus infection (cCMV)
Beyond the preview
Go deeper on 2008-005508-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005508-14.